NCT04877990

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

An Open-label, Multi-center Extension Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Crohn's Disease or Moderate to Severe Ulcerative Colitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 67 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of Deucravacitinib in participants who have previously been enrolled in a Deucravacitinib Phase 2 study for moderate to severe Crohn's disease or moderate to severe Ulcerative Colitis.

Conditions

• Crohn Disease
• Ulcerative Colitis

Interventions

Type	Name	Description
DRUG	Deucravacitinib	Specified dose on specified days

Timeline

• Start date: 2021-05-07
• Primary completion: 2023-08-29
• Completion: 2023-08-29
• First posted: 2021-05-07
• Last updated: 2024-09-24
• Results posted: 2024-09-24

Locations

43 sites across 16 countries: United States, Australia, Canada, China, Germany, Hungary, Italy, Japan, Netherlands, Poland, Portugal, Romania, Russia, Spain, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study